NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Forecast, Price & News $3.02 +0.08 (+2.72%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$2.86▼$3.0250-Day Range$2.89▼$4.2652-Week Range$2.68▼$7.53Volume12,456 shsAverage Volume17,996 shsMarket Capitalization$31.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media TherapeuticsMD MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish3.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to $0.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.98 out of 5 starsMedical Sector958th out of 972 stocksPharmaceutical Preparations Industry443rd out of 449 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for TherapeuticsMD. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.78% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 18.2, which indicates bearish sentiment.Change versus previous monthShort interest in TherapeuticsMD has recently increased by 21.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TXMD. Previous Next 2.4 News and Social Media Coverage News SentimentTherapeuticsMD has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.Search Interest5 people have searched for TXMD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 28.68% of the stock of TherapeuticsMD is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TherapeuticsMD are expected to grow in the coming year, from ($0.75) to $0.15 per share.Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TherapeuticsMD (NASDAQ:TXMD) StockTherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More TXMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXMD Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comStockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)September 22, 2023 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.comOctober 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 20, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Wednesday, underperforms marketAugust 15, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market despite losses on the dayAugust 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsJuly 5, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsOctober 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.July 4, 2023 | thestreet.comTherapeuticsMD Rejected by FDA, Delay Could Be FatalMay 23, 2023 | seekingalpha.comTherapeuticsMD: From Fallen And Forgotten To Cash CowMay 15, 2023 | finance.yahoo.comTherapeuticsMD Announces First Quarter 2023 Financial ResultsMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Tuesday, underperforms marketMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, still underperforms marketMay 3, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Monday, underperforms marketApril 30, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitorsApril 23, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market on strong trading dayApril 14, 2023 | msn.comAll You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyApril 7, 2023 | finance.yahoo.comTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionMarch 13, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Monday when compared to competitorsJanuary 5, 2023 | bizjournals.comTheraputicsMD sells products rights for $153 millionJanuary 3, 2023 | finance.yahoo.comTherapeuticsMD Completes Transaction to License Its Products to Mayne PharmaDecember 26, 2022 | reuters.comTXMD.A - TherapeuticsMD Inc | Stock Price & Latest News | ReutersDecember 19, 2022 | bizjournals.comTechnology & Innovation Roundup: Company will cut 212 employees after failed buyoutDecember 16, 2022 | marketwatch.comTherapeuticsMD Inc. stock falls Thursday, underperforms marketDecember 15, 2022 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, outperforms marketDecember 4, 2022 | finance.yahoo.comTherapeuticsMD Announces Definitive Agreements to License its Products to Mayne PharmaSee More Headlines Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Company Calendar Last Earnings8/14/2023Today10/01/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$112 million Net Margins61.23% Pretax Margin41.70% Return on Equity232.35% Return on Assets34.47% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.37 Sales & Book Value Annual Sales$69.96 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$3.73 per share Price / Book0.81Miscellaneous Outstanding Shares10,570,000Free Float10,448,000Market Cap$31.92 million OptionableOptionable Beta1.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesGovernor Thomas G. Thompson (Age 81)Exec. Chairman Comp: $150kMr. Marlan D. Walker J.D. (Age 47)Chief Exec. Officer Comp: $1.13MMr. Robert G. Finizio (Age 52)Co-Founder Comp: $7.51kMr. Michael C. Donegan (Age 55)Interim CFO & Chief Accounting Officer Comp: $712.59kMs. Daniella Silva (Age 37)Chief Compliance Officer Mr. Benjamin Foulk (Age 53)VP of HR Mr. Bharat Warrier (Age 45)Chief Manufacturing Officer Mr. Douglas SteelmanVP of Market AccessMs. Dedra LydenVP of Strategic Partnerships & InitiativesMore ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXRain OncologyNASDAQ:RAINBiora TherapeuticsNASDAQ:BIORASLAN PharmaceuticalsNASDAQ:ASLNPieris PharmaceuticalsNASDAQ:PIRSView All CompetitorsInsiders & InstitutionsClearline Capital LPBought 35,947 shares on 8/15/2023Ownership: 4.491%Citadel Advisors LLCBought 13,300 shares on 8/15/2023Ownership: 0.000%Tejara Capital LtdBought 13,915 shares on 8/11/2023Ownership: 3.645%BlackRock Inc.Bought 20,995 shares on 8/11/2023Ownership: 1.352%Sanders Morris Harris LLCSold 8,577 shares on 7/11/2023Ownership: 0.247%View All Insider TransactionsView All Institutional Transactions TXMD Stock - Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks. How have TXMD shares performed in 2023? TherapeuticsMD's stock was trading at $5.59 on January 1st, 2023. Since then, TXMD stock has decreased by 46.0% and is now trading at $3.02. View the best growth stocks for 2023 here. Are investors shorting TherapeuticsMD? TherapeuticsMD saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 369,000 shares, an increase of 21.3% from the August 31st total of 304,300 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is currently 18.2 days. Approximately 3.8% of the shares of the stock are sold short. View TherapeuticsMD's Short Interest. When is TherapeuticsMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our TXMD earnings forecast. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its earnings results on Monday, August, 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.17. The company had revenue of $0.44 million for the quarter. TherapeuticsMD had a net margin of 61.23% and a trailing twelve-month return on equity of 232.35%. When did TherapeuticsMD's stock split? TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $3.02. How much money does TherapeuticsMD make? TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $31.92 million and generates $69.96 million in revenue each year. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389. This page (NASDAQ:TXMD) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.